CN101626771A - 梅尼埃病治疗药 - Google Patents
梅尼埃病治疗药 Download PDFInfo
- Publication number
- CN101626771A CN101626771A CN200780049682A CN200780049682A CN101626771A CN 101626771 A CN101626771 A CN 101626771A CN 200780049682 A CN200780049682 A CN 200780049682A CN 200780049682 A CN200780049682 A CN 200780049682A CN 101626771 A CN101626771 A CN 101626771A
- Authority
- CN
- China
- Prior art keywords
- group
- meniere
- composition
- hours
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000027530 Meniere disease Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 69
- 229940124597 therapeutic agent Drugs 0.000 title claims description 27
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 62
- 150000004676 glycans Chemical class 0.000 claims abstract description 51
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 50
- 239000005017 polysaccharide Substances 0.000 claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 88
- 229960002479 isosorbide Drugs 0.000 claims description 85
- 239000004386 Erythritol Substances 0.000 claims description 80
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 80
- 235000019414 erythritol Nutrition 0.000 claims description 80
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 80
- 229940009714 erythritol Drugs 0.000 claims description 80
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 68
- 239000001814 pectin Substances 0.000 claims description 59
- 229920001277 pectin Polymers 0.000 claims description 59
- 235000010987 pectin Nutrition 0.000 claims description 59
- 229960000292 pectin Drugs 0.000 claims description 58
- 229920001285 xanthan gum Polymers 0.000 claims description 48
- 235000010493 xanthan gum Nutrition 0.000 claims description 48
- 239000000230 xanthan gum Substances 0.000 claims description 48
- 229940082509 xanthan gum Drugs 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 40
- 239000000499 gel Substances 0.000 claims description 31
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 29
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 29
- 235000010447 xylitol Nutrition 0.000 claims description 29
- 239000000811 xylitol Substances 0.000 claims description 29
- 229960002675 xylitol Drugs 0.000 claims description 29
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 29
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 28
- 235000010413 sodium alginate Nutrition 0.000 claims description 28
- 239000000661 sodium alginate Substances 0.000 claims description 28
- 229940005550 sodium alginate Drugs 0.000 claims description 28
- 235000011187 glycerol Nutrition 0.000 claims description 23
- 150000002772 monosaccharides Chemical class 0.000 claims description 22
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 21
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 21
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 19
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 19
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 19
- 229920001542 oligosaccharide Chemical class 0.000 claims description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims description 17
- 229920001817 Agar Polymers 0.000 claims description 12
- 239000008272 agar Substances 0.000 claims description 12
- 235000010419 agar Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 229920002907 Guar gum Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 235000010417 guar gum Nutrition 0.000 claims description 10
- 239000000665 guar gum Substances 0.000 claims description 10
- 229960002154 guar gum Drugs 0.000 claims description 10
- 229960002920 sorbitol Drugs 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- -1 POLY-karaya Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229960003487 xylose Drugs 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 95
- 235000000346 sugar Nutrition 0.000 abstract description 43
- 239000008187 granular material Substances 0.000 abstract description 9
- 208000005457 endolymphatic hydrops Diseases 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 description 122
- 206010012735 Diarrhoea Diseases 0.000 description 86
- 241001465754 Metazoa Species 0.000 description 45
- 208000024891 symptom Diseases 0.000 description 40
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 35
- 241000700199 Cavia porcellus Species 0.000 description 31
- 239000012153 distilled water Substances 0.000 description 29
- 230000010412 perfusion Effects 0.000 description 29
- 230000001142 anti-diarrhea Effects 0.000 description 28
- 230000003187 abdominal effect Effects 0.000 description 22
- 230000008859 change Effects 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 19
- 208000019790 abdominal distention Diseases 0.000 description 16
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 16
- 239000007789 gas Substances 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 208000028659 discharge Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000007689 inspection Methods 0.000 description 11
- 238000002559 palpation Methods 0.000 description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 10
- 239000005995 Aluminium silicate Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000521257 Hydrops Species 0.000 description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 10
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 10
- 235000012211 aluminium silicate Nutrition 0.000 description 10
- 229910000323 aluminium silicate Inorganic materials 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000018044 dehydration Effects 0.000 description 9
- 238000006297 dehydration reaction Methods 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 7
- 210000003027 ear inner Anatomy 0.000 description 7
- 230000001788 irregular Effects 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 230000000741 diarrhetic effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000015110 jellies Nutrition 0.000 description 6
- 239000008274 jelly Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 210000000664 rectum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001720 vestibular Effects 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 230000002969 morbid Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 229960003726 vasopressin Drugs 0.000 description 4
- 102000010637 Aquaporins Human genes 0.000 description 3
- 108010063290 Aquaporins Proteins 0.000 description 3
- 101800001144 Arg-vasopressin Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 244000287680 Garcinia dulcis Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004888 Aquaporin 1 Human genes 0.000 description 2
- 108090001004 Aquaporin 1 Proteins 0.000 description 2
- 108010036221 Aquaporin 2 Proteins 0.000 description 2
- 102100034414 Aquaporin-2 Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000003477 cochlea Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- WRNXUQJJCIZICJ-UHFFFAOYSA-N mozavaptan Chemical compound C12=CC=CC=C2C(N(C)C)CCCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C WRNXUQJJCIZICJ-UHFFFAOYSA-N 0.000 description 2
- 229950000546 mozavaptan Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003538 tetroses Chemical class 0.000 description 2
- BDEDPKFUFGCVCJ-UHFFFAOYSA-N 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde Chemical compound O=C1OC(O)CC(C(C=O)=C2O)=C1C1=C2CC(C)(C)C1 BDEDPKFUFGCVCJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 102220358604 c.35C>A Human genes 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000262 cochlear duct Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000003198 secondary alcohol group Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组 | 给予药剂 | 灌流(给予后) |
第1组:对照组 | 蒸馏水 | 3小时后 |
第2组:E1H组 | Ery 2.8g/kg | 1小时后 |
第3组:E2H组 | Ery 2.8g/kg | 2小时后 |
第4组:E3H组 | Ery 2.8g/kg | 3小时后 |
第5组:E6H组 | Ery 2.8g/kg | 6小时后 |
第6组:E12H组 | Ery 2.8g/kg | 12小时后 |
组 | 给予药剂 | 灌流(给予后) |
第11组: | 木糖醇(2.8g/kg)单独 | 3小时后 |
第12组: | 木糖醇(2.8g/kg)+黄原胶(0.2g/kg) | 3小时后 |
组 | 给予药剂 | 灌流(给予后) |
第13组(8只): | IB(2.8g/kg)单独 | 3小时后 |
第14组(7只): | IB(2.8g/kg)+海藻酸钠(0.2g/kg) | 3小时后 |
组 | 给予药剂 | 灌流(给予后) |
第13组(8只): | IB单独(2.8g/kg) | 3小时后 |
第15组(7只): | IB(2.8g/kg)+琼脂(0.3g/kg) | 3小时后 |
组 | 给予药剂 | 灌流(给予后) |
第16组(6只): | 甘油(2.8g/kg)单独 | 3小时后 |
第17组(6只): | 甘油(2.8g/kg)+CMC(0.28g/kg) | 3小时后 |
组 | 给予药剂 | 灌流(给予后) |
第18组(6只): | 木糖(2.8g/kg)单独 | 3小时后 |
第19组(6只): | 木糖(2.8g/kg)+黄原胶(0.2g/kg) | 3小时后 |
组 | 给予药剂 | 灌流(给予后) |
第13组:IB单独 | 异山梨醇2.8g/kg | 3小时后 |
第20组:IB以往品组 | 含有异山梨醇2.8g/kg | 3小时后 |
第21组:IB以往品组 | 含有异山梨醇2.8g/kg | 6小时后 |
第22组:凝胶剂给予组 | IB 2.8g/kg+Al+无机盐 | 3小时后 |
第23组:凝胶剂给予组 | IB 2.8g/kg+Al+无机盐 | 6小时后 |
膜的伸展率(%) | 面积增加率(%) |
36.3±23.3 | 48.2±29.2 |
Claims (17)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2007/050172 WO2008084533A1 (ja) | 2007-01-10 | 2007-01-10 | メニエール病治療薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103917818A Division CN102552310A (zh) | 2007-01-10 | 2007-01-10 | 梅尼埃病治疗药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101626771A true CN101626771A (zh) | 2010-01-13 |
CN101626771B CN101626771B (zh) | 2012-11-14 |
Family
ID=39608438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800496823A Expired - Fee Related CN101626771B (zh) | 2007-01-10 | 2007-01-10 | 梅尼埃病治疗药 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8445461B2 (zh) |
EP (1) | EP2127658A4 (zh) |
KR (1) | KR101406231B1 (zh) |
CN (1) | CN101626771B (zh) |
HK (1) | HK1139064A1 (zh) |
WO (1) | WO2008084533A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727045A (zh) * | 2016-04-15 | 2016-07-06 | 宁波优美科新材料有限公司 | 一种用于治疗梅尼埃病的药物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009116490A1 (ja) * | 2008-03-21 | 2009-09-24 | Takeda Setsuko | メニエール病治療薬 |
FR3101546B1 (fr) * | 2019-10-07 | 2023-11-10 | Roquette Freres | Masquage du goût de l’isosorbide |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816298A (en) * | 1987-11-27 | 1989-03-28 | The Dow Chemical Company | Method of making a granular, cold water dispersible coating composition |
JP2508555B2 (ja) * | 1991-05-24 | 1996-06-19 | 株式会社紀文食品 | 苦味低減方法 |
PT655461E (pt) * | 1993-11-16 | 2000-11-30 | Novartis Ag | Derivados ciclicos de aminoacidos |
WO1996013285A1 (en) * | 1994-10-28 | 1996-05-09 | Innovative Technologies Limited | Dehydrated hydrogels |
US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
JPH11180863A (ja) * | 1997-10-16 | 1999-07-06 | Nikken Chem Co Ltd | メニエ−ル病治療薬 |
JPH11180803A (ja) | 1997-12-19 | 1999-07-06 | Sanyo Kako Kk | 工業用殺菌・静菌安定化製剤とその製法 |
FR2775598A1 (fr) * | 1998-03-06 | 1999-09-10 | Sanofi Sa | Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine |
JP2001226293A (ja) * | 2000-02-17 | 2001-08-21 | Kotaro Kanpo Seiyaku Kk | 服用補助剤 |
WO2006001344A1 (ja) * | 2004-06-24 | 2006-01-05 | Sanwa Kagaku Kenkyusho Co., Ltd. | イソソルビド含有ゼリー製剤 |
JP3947796B2 (ja) * | 2005-06-21 | 2007-07-25 | 節子 竹田 | メニエール病治療薬 |
JP4105732B2 (ja) * | 2006-03-01 | 2008-06-25 | 節子 竹田 | メニエール病治療薬 |
JP4167283B2 (ja) | 2006-09-28 | 2008-10-15 | 節子 竹田 | 甘味料 |
CN101164544A (zh) * | 2006-10-19 | 2008-04-23 | 云南白药集团股份有限公司 | 用于静脉滴注的豆腐果苷粉针剂及制备方法 |
JP4081131B1 (ja) | 2007-01-10 | 2008-04-23 | 節子 竹田 | メニエール病治療薬 |
JP4071818B1 (ja) | 2007-01-10 | 2008-04-02 | 節子 竹田 | 甘味料 |
JP4113242B1 (ja) | 2007-01-10 | 2008-07-09 | 節子 竹田 | 消化器症状の防止剤 |
JP4122371B1 (ja) | 2007-01-10 | 2008-07-23 | 節子 竹田 | メニエール病治療薬 |
JP4311453B2 (ja) | 2007-01-26 | 2009-08-12 | ソニー株式会社 | レーザ光源装置及びこれを用いた画像生成装置 |
JP5101911B2 (ja) | 2007-03-20 | 2012-12-19 | パナソニック株式会社 | ドレン蓋 |
JP5356655B2 (ja) | 2007-03-20 | 2013-12-04 | パナソニック株式会社 | 集水ます蓋 |
WO2009116490A1 (ja) | 2008-03-21 | 2009-09-24 | Takeda Setsuko | メニエール病治療薬 |
-
2007
- 2007-01-10 US US12/448,804 patent/US8445461B2/en not_active Expired - Fee Related
- 2007-01-10 CN CN2007800496823A patent/CN101626771B/zh not_active Expired - Fee Related
- 2007-01-10 KR KR1020097015925A patent/KR101406231B1/ko not_active IP Right Cessation
- 2007-01-10 WO PCT/JP2007/050172 patent/WO2008084533A1/ja active Search and Examination
- 2007-01-10 EP EP07706519A patent/EP2127658A4/en not_active Withdrawn
-
2010
- 2010-05-26 HK HK10105173.6A patent/HK1139064A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727045A (zh) * | 2016-04-15 | 2016-07-06 | 宁波优美科新材料有限公司 | 一种用于治疗梅尼埃病的药物 |
Also Published As
Publication number | Publication date |
---|---|
US8445461B2 (en) | 2013-05-21 |
HK1139064A1 (en) | 2010-09-10 |
WO2008084533A1 (ja) | 2008-07-17 |
KR20100014346A (ko) | 2010-02-10 |
CN101626771B (zh) | 2012-11-14 |
EP2127658A1 (en) | 2009-12-02 |
KR101406231B1 (ko) | 2014-06-12 |
EP2127658A4 (en) | 2011-04-27 |
US20100120712A1 (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis | |
US20050155519A1 (en) | Granulation process | |
CN101626771B (zh) | 梅尼埃病治疗药 | |
WO2009036906A1 (de) | Zusammensetzung mit wirkstoffkombination aus einem laxans und einem entschäumer zur behandlung von obstipation | |
CN102552310A (zh) | 梅尼埃病治疗药 | |
JP4113242B1 (ja) | 消化器症状の防止剤 | |
JP3947796B2 (ja) | メニエール病治療薬 | |
CN108366991A (zh) | 用于治疗和/或预防粘膜的干燥和刺激的吡咯烷酮羧酸和/或其盐与透明质酸和/或其盐的协同配混物、及相关的药物制剂 | |
JP4122371B1 (ja) | メニエール病治療薬 | |
JP4167283B2 (ja) | 甘味料 | |
JP4081131B1 (ja) | メニエール病治療薬 | |
JP4071818B1 (ja) | 甘味料 | |
CN112386577B (zh) | 一种治疗便秘的组合物 | |
JP4385343B2 (ja) | メニエール病治療薬 | |
CN111467356B (zh) | 含有l-阿拉伯糖的治疗便秘的药物组合物及其应用方法 | |
CN103877533B (zh) | 一种含有二甲双胍的治疗糖尿病的药物组合物及其制备方法 | |
WO2009116490A1 (ja) | メニエール病治療薬 | |
EP3311814A1 (en) | Purgative composition for cleansing intestinal tract | |
CN100508987C (zh) | 玻璃酸在制备用于预防或改善眼玻璃体变性疾病的口服产品中的应用 | |
JP4865924B2 (ja) | メニエール病治療薬 | |
JP4676522B6 (ja) | メニエール病治療薬 | |
JP6355806B1 (ja) | ラクツロースを有効成分とする便秘症治療剤 | |
CN105688080A (zh) | 治疗痰火扰心证型广泛性焦虑症的中药制剂 | |
CN109091494A (zh) | 羧酸基团修饰的水溶性淀粉盐在预防和治疗便秘中的应用 | |
JP2007230990A (ja) | メニエール病治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1139064 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TAKEDA SETSUKO Free format text: FORMER OWNER: KOWA COMPANY LTD. Effective date: 20130515 Free format text: FORMER OWNER: TAKEDA SETSUKO Effective date: 20130515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130515 Address after: Hyogo Patentee after: Takeda Setsuko Address before: Aichi Patentee before: Kowa Co., Ltd. Patentee before: Takeda Setsuko |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1139064 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121114 Termination date: 20140110 |